In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

Johnson & Johnson said it received positive topline results in a Phase 3 study of a combination of drugs to treat patients with locally advanced or metastatic non-small cell lung cancer.

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...